Although disease-modifying therapies for ADPKD remain limited, metformin has attracted attention because of its antiproliferative properties, mediated via activation of AMPK/mTOR/CFTR pathways involved in cystogenesis [4, 8, 12]. This evidence concerns the gene MTOR and autosomal dominant polycystic kidney disease.